Home › Compare › DQJCY vs ABBV
DQJCY yields 0.78% · ABBV yields 3.06%● Live data
📍 DQJCY pulled ahead of the other in Year 7
Combined, DQJCY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DQJCY + ABBV for your $10,000?
Pan Pacific International Holdings Corporation, together with its subsidiaries, operates retail stores. It operates through three segments: Discount Store Business, General Merchandise Store (GMS) Business, and Rent Business. The Discount Store Business segment operates convenience and discount stores under the Don Quijote name; and general discount stores under the MEGA Don Quijote and MEGA Don Quijote UNY names. The GMS Business segment operates general supermarkets under the APITA name; and small-scale supermarkets under the PIAGO name. The Rent Business segment rents and manages retail properties to tenants. The company is also involved in the real estate management business. As of October 31, 2020, it operated 631 stores comprising 579 stores in Japan; 28 stores in Hawaii and 10 stores in California, the United States; 4 stores in Hong Kong; 2 stores in Thailand; and 8 stores in Singapore. The company was formerly known as Don Quijote Holdings Co., Ltd. and changed its name to Pan Pacific International Holdings Corporation in February 2019. Pan Pacific International Holdings Corporation was founded in 1980 and is headquartered in Tokyo, Japan.
Full DQJCY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.